Company type | Private |
---|---|
Industry | Pharmaceuticals |
Founded | San Diego, California, United States (1988) |
Founder | Michael A. Palladino, Kobi M. Sethna, Stan Fleming, William Fenical |
Headquarters | San Diego, California, United States |
Key people | Michael A. Palladino Ph.D.(Scientific Co-founder, SVP and Chief Technology Officer) Kobi M. Sethna (President, CEO)
[1] Gary Shearman (Chairman of the Board) [2] G. |
Number of employees | 36 [3] |
Website | www.nereuspharm.com |
Nereus Pharmaceuticals was a pharmaceutical company focused on the development of natural products from marine microbial and other natural sources into small molecule human therapeutics. [4] The major disease area addressed by Nereus is cancer. Nereus was purchased by Triphase Research and Development in 2012. [5]
Until 2004, Nereus used methods licensed from the University of California, San Diego to retrieve and cultivate marine microorganisms, particularly bacteria in the Actinomycetia class and organisms belonging to Kingdom Fungi. [4] Since 2004, the company has focused on commercializing identified bioactive natural products. [4] As of mid-2007, two compounds were being examined in Phase I clinical trials: NPI-2358 and NPI-0052. [4]
Number of employees - 36
Nereus mines microorganisms collected from the ocean to find new small molecule drug candidates, much like older pharmaceutical companies discovered new drugs by screening soil.
Isolated from coarse sand off the Bahamas. The type strain is CNB-440T (=ATCC BAA-916T=DSM 44818T). (from Results & Discussion section)
Company type | Private |
---|---|
Industry | Pharmaceuticals |
Founded | San Diego, California, United States (1988) |
Founder | Michael A. Palladino, Kobi M. Sethna, Stan Fleming, William Fenical |
Headquarters | San Diego, California, United States |
Key people | Michael A. Palladino Ph.D.(Scientific Co-founder, SVP and Chief Technology Officer) Kobi M. Sethna (President, CEO)
[1] Gary Shearman (Chairman of the Board) [2] G. |
Number of employees | 36 [3] |
Website | www.nereuspharm.com |
Nereus Pharmaceuticals was a pharmaceutical company focused on the development of natural products from marine microbial and other natural sources into small molecule human therapeutics. [4] The major disease area addressed by Nereus is cancer. Nereus was purchased by Triphase Research and Development in 2012. [5]
Until 2004, Nereus used methods licensed from the University of California, San Diego to retrieve and cultivate marine microorganisms, particularly bacteria in the Actinomycetia class and organisms belonging to Kingdom Fungi. [4] Since 2004, the company has focused on commercializing identified bioactive natural products. [4] As of mid-2007, two compounds were being examined in Phase I clinical trials: NPI-2358 and NPI-0052. [4]
Number of employees - 36
Nereus mines microorganisms collected from the ocean to find new small molecule drug candidates, much like older pharmaceutical companies discovered new drugs by screening soil.
Isolated from coarse sand off the Bahamas. The type strain is CNB-440T (=ATCC BAA-916T=DSM 44818T). (from Results & Discussion section)